Results:
The highest rate of HCC progression on the waiting list was observed in the extra-UCSF group of patients (36% versus 11% (p = 0.03) and 15% (p = 0.1) in the “Milan” and “Lerut” groups, respectively).
Statistically significant differences were found in the level of cancer-associated mortality and median disease-free survival, with the worst rates in the extra-UCSF group. The one-year, three-year and five-year overall survival rate in the groups were
87.5%; 80.1% and 70.3% for the Milan group;
78.6%; 62.9% and 62.9% for the extra-UCSF group and
96.4%; 86.4% and 78.7% for the Lerut group, respectively.
Conclusion:
The oncological prognosis of patients with HCC is informed not only from the size and number of tumour foci as from the biological characteristics of the tumour. LRT combines both a therapeutic option, that allows reach better survival, and a stratification option, that enable patients to wait for liver transplantation beyond the accepted criteria.